Rosiglitazone (Avandia) suspended from the Saudi Arabian market The Saudi Food and Drug Authority (SFDA) announced on March 14, 2010 that the marketing authorization for rosiglitazone (Avandia) and all combination products containing rosiglitazone was suspended for safety reasons. The suspension is for a period of six months during which time no rosiglitazone or rosiglitazone containing … [Read more...]

Press release December 2007 Contact: Christophe Kopp ckopp@prescrire.org Nimesulide must be withdrawn worldwide due to serious liver damage Nimesulide exposes patients to fatal liver damage. When a non-steroidal anti-inflammatory drug is needed, it is better to use one with a favourable benefit-harm balance such as ibuprofen. EU authorities fail to protect consumers. The … [Read more...]